Similar to other studies, our CRC PDX tumors match patient response to 5-FU [37,38,89,90,91], and can be utilized to understand response to targeted therapies, like cetuximab, an anti-EGFR antibody [37]. Here, EGFR is linked to colorectal carcinoma.